In Silico prediction of the molecular basis of ClTx and AaCTx interaction with matrix metalloproteinase-2 (MMP-2) to inhibit glioma cell invasion.
Glioblastoma is the deadliest type of brain cancer. Treatment could target the Matrix metalloproteinase-2 (MMP-2), which is known to be involved in the invasion process of glioblastoma cells. But current available inhibitors are not selective to MMP-2 due to their interaction with the catalytic binding site, which is highly conserved in all MMPs structures. Interestingly, members of the chloride channel blocker scorpion toxins, such as chlorotoxin (ClTx) and AaCTx, inhibit glioblastoma cell invasion and show a promising therapeutic potential. Indeed, it has been shown that CITx inhibits selectively MMP-2 and was also able to cross the blood brain and tissue barriers. Although ClTx and AaCTx show high sequence similarity, AaCTx is ten times less active than ClTx. By using molecular modeling, molecular dynamics and MM-PB(GB)SA free energy estimation, we present the first computational study reporting the interaction mode of ClTx/AaCTx with MMP-2. We found that the two peptides probably act on an exosite of MMP-2 comprising mainly residues from the collagen binding domain, a feature that could be exploited to enhance the selectivity toward MMP-2. van der Waals and hydrophobic forces are the primary mediators of this interaction. The N- and C-termini of the two peptides harbor the key residues of the interaction spread across a conserved amino acid patch. In particular, F6 contributes mostly to the binding free energy in ClTx. We also suggest that the lack of the C-terminal arginine and the residues P10 and R24, might be responsible for altering the activity of AaCTx toward glioblastoma cells compared to ClTx.
a Laboratory of venoms and therapeutic biomolecules (LR11IPT08) , Institut Pasteur de Tunis , Tunis , Tunisia .|b Faculté des Sciences de Bizerte , Université de Carthage , Bizerte , Tunisia .
Houcemeddine
H
Othman
c Département de Biologie Structurale et Chimie , Institut Pasteur, Unité de Bioinformatique Structurale , Paris , France .
Silke Andrea
SA
Wieninger
a Laboratory of venoms and therapeutic biomolecules (LR11IPT08) , Institut Pasteur de Tunis , Tunis , Tunisia .
Mohamed
M
ElAyeb
c Département de Biologie Structurale et Chimie , Institut Pasteur, Unité de Bioinformatique Structurale , Paris , France .
Michael
M
Nilges
a Laboratory of venoms and therapeutic biomolecules (LR11IPT08) , Institut Pasteur de Tunis , Tunis , Tunisia .
Najet
N
Srairi-Abid
D001120:Arginine / Q000378:metabolism; D001665:Binding Sites / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism; D045744:Cell Line, Tumor; D003198:Computer Simulation; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D056004:Molecular Dynamics Simulation; D009361:Neoplasm Invasiveness / Q000473:pathology*; D010455:Peptides / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D012604:Scorpion Venoms / Q000494:pharmacology*
D010455:Peptides; D012604:Scorpion Venoms; C091539:Chlorotoxin; D001120:Arginine; D020778:Matrix Metalloproteinase 2
MMP-2; chlorotoxin; collagen binding domain; glioblastoma; molecular modeling